Early research (Phase 1)Study completedNCT00798343What this trial is testingHeterosubtypic Immune Responses to Influenza in Older PeopleWho this might be right forInfluenza University Hospitals, Leicester 292
Testing effectiveness (Phase 2)Study completedNCT01323946What this trial is testingStudy to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in ChildrenWho this might be right forInfluenza GlaxoSmithKline 113
Testing effectiveness (Phase 2)Study completedNCT00742885What this trial is testingImmunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate VaccineWho this might be right forInfluenza GlaxoSmithKline 100
Large-scale testing (Phase 3)WithdrawnNCT00866580What this trial is testingEvaluation of GSK Biologicals' Pandemic Influenza VaccineWho this might be right forInfluenza GlaxoSmithKline
Post-approval studies (Phase 4)Study completedNCT01730378What this trial is testingImmunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years OldWho this might be right forInfluenza GlaxoSmithKline 131
Large-scale testing (Phase 3)Study completedNCT00848029What this trial is testingSafety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination SchedulesWho this might be right forPre-pandemic Influenza Vaccine Novartis Vaccines 240
Not applicableStudy completedNCT05620953What this trial is testingSevere Acute Respiratory Infections (SARI) in Belgium (2011-2020)Who this might be right forInfluenza Viral InfectionsRespiratory Viral InfectionSevere Acute Respiratory Infection Sciensano 12,145
Large-scale testing (Phase 3)Study completedNCT01987011What this trial is testingPhase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersWho this might be right forInfluenza Green Cross Corporation 420
Testing effectiveness (Phase 2)Study completedNCT01389466What this trial is testingStudy to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult VolunteersWho this might be right forInfluenza Green Cross Corporation 346
Testing effectiveness (Phase 2)Study completedNCT00537524What this trial is testingImmunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsWho this might be right forProphylaxis of Avian Influenza Novartis Vaccines 471